Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Feb;7(Suppl 1):S35-S38.
doi: 10.21037/tlcr.2018.01.05.

Putting the brakes on CTLA-4 inhibition in lung cancer?

Meghan J Mooradian  1 , Justin F Gainor  1
Affiliations
Editorial

Putting the brakes on CTLA-4 inhibition in lung cancer?

Meghan J Mooradian et al. Transl Lung Cancer Res. 2018 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: JF Gainor has served as a compensated consultant or received honoraria from Bristol-Myers Squibb, Genentech/Roche, Merck, Incyte, Array Biopharma, Novartis, Pfizer, Ariad/Takeda, Loxo and Theravance. MJ Mooradian has no conflicts of interest to declare.

Comment on

References

    1. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2016;375:1823-33. 10.1056/NEJMoa1606774 - DOI - PubMed
    1. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 2015;373:123-35. 10.1056/NEJMoa1504627 - DOI - PMC - PubMed
    1. Borghaei H, Brahmer J, Horn L, et al. P2.35: Nivolumab vs Docetaxel in Advanced NSCLC: CheckMate 017/057 2-Y Update and Exploratory Cytokine Profile Analysis: Track: Immunotherapy. J Thorac Oncol 2016;11:S237-8. 10.1016/j.jtho.2016.08.106 - DOI - PubMed
    1. Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 2016;387:1837-46. 10.1016/S0140-6736(16)00587-0 - DOI - PubMed
    1. Govindan R, Szczesna A, Ahn MJ, et al. Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer. J Clin Oncol 2017;35:3449-57. 10.1200/JCO.2016.71.7629 - DOI - PubMed

LinkOut - more resources